Dataset Information


PSGL-1-mediated activation of EphB4 increases the proangiogenic potential of endothelial progenitor cells.

ABSTRACT: Endothelial progenitor cell (EPC) transplantation has beneficial effects for therapeutic neovascularization; however, only a small proportion of injected cells home to the lesion and incorporate into the neocapillaries. Consequently, this type of cell therapy requires substantial improvement to be of clinical value. Erythropoietin-producing human hepatocellular carcinoma (Eph) receptors and their ephrin ligands are key regulators of vascular development. We postulated that activation of the EphB4/ephrin-B2 system may enhance EPC proangiogenic potential. In this report, we demonstrate in a nude mouse model of hind limb ischemia that EphB4 activation with an ephrin-B2-Fc chimeric protein increases the angiogenic potential of human EPCs. This effect was abolished by EphB4 siRNA, confirming that it is mediated by EphB4. EphB4 activation enhanced P selectin glycoprotein ligand-1 (PSGL-1) expression and EPC adhesion. Inhibition of PSGL-1 by siRNA reversed the proangiogenic and adhesive effects of EphB4 activation. Moreover, neutralizing antibodies to E selectin and P selectin blocked ephrin-B2-Fc-stimulated EPC adhesion properties. Thus, activation of EphB4 enhances EPC proangiogenic capacity through induction of PSGL-1 expression and adhesion to E selectin and P selectin. Therefore, activation of EphB4 is an innovative and potentially valuable therapeutic strategy for improving the recruitment of EPCs to sites of neovascularization and thereby the efficiency of cell-based proangiogenic therapy.

PROVIDER: S-EPMC1866248 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC2866036 | BioStudies
| S-EPMC6522285 | BioStudies
| S-EPMC3237458 | BioStudies
| S-EPMC397426 | BioStudies
| S-EPMC6127455 | BioStudies
| S-EPMC4108521 | BioStudies
| S-EPMC3807243 | BioStudies
| S-EPMC5127687 | BioStudies
| S-EPMC3787464 | BioStudies
| S-EPMC2803108 | BioStudies